https://ellisenlab.com/portfolio/expressed-gene-fusions-as-frequent-drivers-of-poor-outcomes-in-hormone-receptor-positive-breast-cancer/2022-09-14T20:02:14+00:00https://ellisenlab.com/portfolio/unravelling-subclonal-heterogeneity-and-aggressive-disease-states-in-tnbc-through-single-cell-rna-seq/2022-09-14T20:01:08+00:00https://ellisenlab.com/portfolio/actl6a-is-co-amplified-with-p63-in-squamous-cell-carcinoma-to-drive-yap-activation-regenerative-proliferation-and-poor-prognosis/2022-09-14T20:03:24+00:00https://ellisenlab.com/portfolio/antibody-drug-conjugate-sacituzumab-govitecan-enables-a-sequential-top1-parp-inhibitor-therapy-strategy-in-patients-with-breast-cancer/2024-07-19T18:30:37+00:00https://ellisenlab.com/portfolio/basal-cell-signaling-by-p63-controls-luminal-progenitor-function-and-lactation-via-nrg1/2020-01-25T06:48:01+00:00https://ellisenlab.com/portfolio/aneuploidy-and-a-deregulated-dna-damage-response-suggest-haploinsufficiency-in-breast-tissues-of-brca2-mutation-carriers/2020-04-30T01:06:23+00:00https://ellisenlab.com/portfolio/redd1-loss-reprograms-lipid-metabolism-to-drive-progression-of-ras-mutant-tumors/2022-09-14T19:57:28+00:00https://ellisenlab.com/portfolio/a-mutational-signature-reveals-alterations-underlying-deficient-homologous-recombination-repair-in-breast-cancer/2021-02-08T23:01:44+00:00https://ellisenlab.com/portfolio/parallel-genomic-alterations-of-antigen-and-payload-targets-mediate-polyclonal-acquired-clinical-resistance-to-sacituzumab-govitecan-in-triple-negative-breast-cancer/2022-09-14T19:56:07+00:00